Anti-oxidant, anti-estrogenic and anti-inflammatory activities of the UHPLC fingerprinted Acacia seyal Delile (Mimosaceae) extracts: possible anticancer modes of action.

Associations between physical activity, body esteem, and self-esteem among women with breast and gynecological cancer.

While alcohol consumption appears to influence the incidence of breast cancer (BC), its association with prognosis after a BC diagnosis remains less established. This meta-analysis aimed to explore the association between alcohol consumption on both BC incidence and outcomes. A systematic literature search was conducted up to May 1st, 2025 (CRD42025593784). Retrospective and prospective studies reporting BC incidence, recurrences, and survival outcomes in women with history of alcohol consumption were included. Analyses according to alcohol intake levels (light, intermediate, heavy consumption) were performed. Main outcomes were BC incidence, BC recurrences, BC-specific survival (BCSS), and overall survival (OS). Pooled relative risk (RR) and hazard ratio (HR) with 95% confidence interval (CI) were calculated. Out of 5208 screened records, 37 studies including 2,565,920 women were included. Among 17 studies reporting on BC incidence, any alcohol consumption was associated with an increased BC incidence (RR 1.17, 95%CI 1.09-1.26; p<0.001). BC incidence increased proportionally with higher levels of alcohol consumption: light RR 1.13 (95%CI 1.05-1.23; p=0.002), intermediate RR 1.28 (95%CI 1.18-1.39; p<0.001)​, and heavy consumption RR 1.52 (95%CI 1.38-1.67; p<0.001). Among 20 studies assessing BC outcomes, no associations were found between alcohol consumption and BC recurrences (RR 1.02, 95%CI 0.93-1.11) nor BCSS (HR 0.93, 95%CI 0.87-1.00), while light and intermediate alcohol consumption were associated with slightly improved OS: HR 0.85 (95%CI 0.78-0.92; p<0.001) and HR 0.84 (95%CI 0.75-0.94; p=0.002), respectively. Among over 2.5 million women, alcohol consumption was associated with a dose-dependent increased risk of BC, while alcohol consumption did not appear to worsen prognosis in patients with prior BC diagnosis.

Specific variations in cfDNA methylation level of CDH1 and Gjb1 in a mouse model with breast cancer before and after metastasis.

SELE is associated with reduced breast cancer susceptibility: Evidence from Mendelian randomization and single-cell transcriptome.

The incidence and risk factors for brain metastases among patients with stage I-III breast cancer remain poorly defined. We conducted a population-based cohort study using Ontario health administrative databases to identify patients diagnosed with stage I-III breast cancer between 2009 and 2021. Treatment of brain metastases with surgery or radiation was extracted from the same databases. Patients were stratified by breast cancer subtype: human epidermal growth factor receptor 2 positive/hormone receptor positive (HER2+/HR+), HER2+/hormone receptor negative (HER2+/HR-), HR+/HER2-, and triple-negative breast cancer (TNBC). Primary outcomes were the cumulative incidence of treated brain metastases and time to brain metastasis (TTBM) as defined by the time from primary breast cancer diagnosis to brain metastases treatment. Among 92,973 patients, 7.9% had HER2+/HR+, 3.5% HER2+/HR-, 54.1% HR+/HER2-, 7.3% TNBC, and 27.2% unknown subtype. Median (IQR) follow-up was 84.2 (50.8-125.2) months. The 12-year cumulative incidence of treated brain metastases was 2.8% in the overall cohort. Among patients with stage III disease, 12-year incidence was 11.8% (HER2+/HR+), 14.3% (HER2+/HR-), 5.9% (HR+/HER2-), and 13.4% (TNBC); corresponding 5-year incidences were 7.5%, 11.2%, and 13.1% for stage III HER2+/HR+, HER2+/HR-, and TNBC, respectively. Among patients with stage III HER2+/HR- and TNBC, median TTBM was 23.3 and 18.0 months, respectively. Up to 13% of patients with stage III HER2+ or TNBC received treatment for brain metastases within 5 years of diagnosis with early-stage breast cancer. These findings support prospective studies of risk-stratified screening for asymptomatic brain metastases in patients with early-stage breast cancer.

The mediating role of the intimate relationship between dyadic coping and reproductive concerns in couples of childbearing age facing breast cancer: A cross-sectional study.

Biomarker recall and understanding among people living with metastatic breast cancer - results from an international patient survey.

Title: Impact of CYP3A5*3 genetic polymorphism on breast cancer risk: Evidence from Bangladesh.

Tripartite motif-containing 37 (TRIM37) is an E3 ubiquitin ligase that epigenetically silences tumor suppressors in DNA repair, regulates polo-like kinase 4, promotes chromosomal instability, and functions as an oncogenic driver in breast cancer (BC). Preclinical studies have implicated TRIM37 in chemotherapy resistance, particularly in triple-negative breast cancer (TNBC), and TRIM37-targeted therapy is in development. However, TRIM37 has not been fully investigated in patients with BC, so its prognostic and therapeutic significance remains unclear. TRIM37 expression was analyzed in 6558 patients across four large, independent cohorts with transcriptome data (METABRIC, TCGA, SCAN-B, and GSE25066). TRIM37 expression was higher in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative BC than in TNBC, and it was associated with worse disease-free, disease-specific, and overall survival in ER-positive/HER2-negative BC but not in TNBC. TRIM37 expression was significantly associated with DNA repair pathways, homologous recombination deficiency, mutation rates, and enhanced cancer cell proliferation, as evidenced by Nottingham histological grade, Ki67 expression, and gene set enrichment analysis. TRIM37 expression correlated with reduced immune activity, lower cytolytic activity, and decreased response to neoadjuvant chemotherapy in ER-positive/HER2-negative BC, whereas TRIM37-high TNBC displayed higher neoantigen burden and improved chemotherapy response. TRIM37 expression is associated with increased cell proliferation, regardless of subtype; however, it is strongly associated with reduced immune activity, worse response to chemotherapy, and poor prognosis in ER-positive/HER2-negative BC, whereas it was associated with better response to chemotherapy and no relationship with survival in TNBC. Our results provide critical insights into the clinical application of TRIM37-targeted therapies.

The MCM/Lys-Cys nanodevices for the efficient gene delivery: An approach towardsMCP1gene manipulation using CRISPR technology.

Why does EGFR-targeted therapy continue to fail in breast cancer? From mechanistic deciphering to novel intervention strategies.

Global breast cancer incidence, mortality, and survival among indigenous women: A systematic review and meta-analysis.

Global mammographic asymmetry (GA) is generally considered benign, and its association with subsequent breast cancer risk is unclear. We examined whether GA on screening mammography predicts short-term and long-term breast cancer and whether this varies by Breast Imaging Reporting and Data System (BI-RADS) breast density. In this retrospective cohort study using the Korean National Health Insurance Service screening programme, we included women aged ≥40 years who underwent screening mammography in 2009-2010 and had no prior breast cancer. GA and BI-RADS density were recorded on baseline mammograms; incident invasive breast cancer through December 31, 2019 was ascertained from insurance claims. Cox proportional hazards models estimated adjusted hazard ratios (aHRs) for breast cancer associated with GA overall and by BI-RADS density and follow-up interval (<1, 1-2 and ≥2 years), adjusting for demographic, reproductive and lifestyle factors. Among 5,475,113 women, GA was present in 4.0%. Overall, GA was associated with a modestly increased breast cancer risk (aHR 1.15; 95% CI 1.11-1.19), strongest within 1 year of screening (aHR 1.90; 95% CI 1.70-2.12). In women with BI-RADS 1 breasts, GA doubled overall risk (aHR 2.03) and quadrupled short-term risk (<1 year: aHR 4.14), whereas in BI-RADS 4 breasts GA did not increase overall risk (aHR 0.94). GA is uncommon but identifies women at substantially elevated short-term breast cancer risk, particularly those with non-dense breasts, and has limited long-term prognostic value in extremely dense breasts. These findings support consideration of short-interval follow-up or supplemental imaging when GA is reported in non-dense breasts.

An integrative multi-omics analysis leveraging Mendelian randomization and subsequent experimental validation prioritizes glutathione S-transferase mu 5 (GSTM5) as a genomic stability-related gene and a therapeutic vulnerability to PLK1 inhibition in breast cancer.

Signet-ring cell cytomorphology in breast cancer: Unveiling the overlooked.

Chemotherapy resistance is the primary cause of clinical treatment failure and unfavorable prognosis among breast cancer patients. Consequently, the exploration of novel molecular targets for chemotherapy resistance is warranted. Here, we demonstrated that Zinc Finger Protein 184 (ZNF184) facilitates chemoresistance in breast cancer. Through integrated bioinformatics and experimental validation, we identified that ZNF184 was highly expressed in paclitaxel-resistant breast cancer cells. Knockdown of ZNF184 inhibited cell proliferation and re-sensitized resistant cells to paclitaxel in vitro and in patients-derived organoids (PDOs). Mechanistically, ZNF184 regulates the expression of stemness-related genes CD44, OCT4, Nanog, SOX2, and ALDH1A1, thereby promoting the proliferation of breast cancer cells and subsequent paclitaxel resistance. Pan-cancer analysis revealed the potential of ZNF184 as a prognostic and predictive biomarker for adverse clinical outcomes. Collectively, these findings reveal a previously unknown role of ZNF184 in breast cancer progression and paclitaxel resistance, providing new insights into ZNF184 as a potential therapeutic target for cancer patients.

Breast cancer genetics and risk assessment 101: What women's health care providers need to know.

Transcriptional and Pathway Level Heterogeneity in Luminal A Breast Cancer: A Framework for Precision Therapy.

Breast cancer (BC) ranks as the second most prevalent malignant tumor among women globally, posing a significant threat to female health. Obesity is recognized as an independent risk factor for both the development and progression of BC. Nevertheless, due to the complex mechanism through which obesity affects BC, coupled with the considerable variations in hormone levels, metabolic states, and treatment responses between premenopausal and postmenopausal women, epidemiological studies examining the relationship between obesity and BC incidence often produce inconsistent results. Consequently, it is imperative to stratify analyses by menopausal status to elucidate the specific impact of obesity on BC and to inform targeted prevention strategies.